BidaskClub downgraded shares of Sinovac Biotech (NASDAQ:SVA) from a buy rating to a hold rating in a report published on Wednesday, December 27th.
Shares of Sinovac Biotech (SVA) opened at $8.05 on Wednesday. The stock has a market cap of $456.15, a PE ratio of -804.20 and a beta of 0.13. Sinovac Biotech has a one year low of $4.60 and a one year high of $8.11.
Several institutional investors and hedge funds have recently bought and sold shares of the company. State Street Corp boosted its stake in shares of Sinovac Biotech by 18.5% in the 2nd quarter. State Street Corp now owns 49,281 shares of the biopharmaceutical company’s stock valued at $333,000 after purchasing an additional 7,711 shares in the last quarter. Citadel Advisors LLC boosted its stake in shares of Sinovac Biotech by 189.8% in the 3rd quarter. Citadel Advisors LLC now owns 34,193 shares of the biopharmaceutical company’s stock valued at $241,000 after purchasing an additional 22,393 shares in the last quarter. SG Americas Securities LLC bought a new position in Sinovac Biotech in the 3rd quarter valued at approximately $163,000. Renaissance Technologies LLC raised its holdings in Sinovac Biotech by 8.0% in the 2nd quarter. Renaissance Technologies LLC now owns 1,814,300 shares of the biopharmaceutical company’s stock valued at $12,247,000 after buying an additional 134,810 shares during the last quarter. Finally, GLG Partners LP raised its holdings in Sinovac Biotech by 144.8% in the 2nd quarter. GLG Partners LP now owns 282,611 shares of the biopharmaceutical company’s stock valued at $1,908,000 after buying an additional 167,165 shares during the last quarter. Institutional investors own 31.80% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Sinovac Biotech (SVA) Downgraded to “Hold” at BidaskClub” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/14/sinovac-biotech-sva-downgraded-by-bidaskclub.html.
About Sinovac Biotech
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps.
Receive News & Ratings for Sinovac Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech and related companies with MarketBeat.com's FREE daily email newsletter.